The status analysis of truth-telling of cancer in China
The total incidence rates of cancer in China is gradually increasing each year, and cancer has become one of the most life-threatening illness. Telling truth to cancer patients is not only a legal obligation, but also affects the humanistic care of cancer treatment. In China, whether doctors should tell truth to cancer patients is still in dispute among relatives of patients, and even among doctors. People of diff erent ages have obviously diff erent understandings of truth-telling in China, which is aff ected by education level, family roles, and traditional customs. Truth-telling of cancer is not only a matter between the doctor and the patient, but also involves the doctor and the patient and their relatives. Traditional customs and financial capability are important factors that influence the understanding of cancer and therapeutic strategy selection. The vast majority of oncologists in China believe that telling truth to cancer patients has more benefi ts in terms of individual rights, disease treatment, and humanistic care. The doctors need to master excellent communication skills and truth-telling way full of humanistic care.
Truth-telling of cancer, China, humanistic care, cancer treatment
宋 纯※1、张 顺、蒋小华
The status and problems of truth-telling in Chinese oncology surgery
Attitudes and practices of truth-telling to patients with cancer in China have shifted in the past few years. However, cultural and individual diff erences persist, and some diffi culties common to all medical specialties are magnifi ed in oncology. Thetruth-telling plays important role in the doctor-patient relationship in China. This review shows the status and problems of truth-telling in China, especially in aspect of patients receiving oncology surgery.
China, Oncology, Truth-telling, Cancer patients
The current situation and problems/challenges giving a notice about cancer in Japan
Several cancer genome profi ling tests, called CGP tests are available to the public in the world. In Japan, two types of CGP test, covered by Japanese Health insurance system has started. The patient applied for CGP test, is limited. In addition to that, results from CGP test is open to a number of interpretations, it depends on“ expert panel”. We have to learn about characteristics of each CGP tests and benefi t all cancer patients.
precision cancer medicine, cancer gene profi ling test, hereditary neoplastic syndrome, genotype matched treatment, disclosure of genetic information
Status and Issues of Cancer Genome Risk Notification in Japan
Japan has just entered the era of cancer genomic medicine. As genetic information is rapidly coming into general medical care, both healthcare professionals and patients have been required to have not only cancer literacy but also genomic literacy. In this era, patients should be supported by genetic counseling, and be able to seek cancer preventive medical care by themselves. Currently, only ～10% of new treatments can be found by clinical sequences. Meanwhile, incidental fi ndings can be occasionally found by clinical sequences. In this review, we will address our status and problems in Japan regarding cancer genome risk notification.
cancer genome, clinical sequence, incidental fi ndings, literacy, preventive medicine
笹川生 in China
|后 记||宣传委员会委员 樋野兴夫|